-
Mashup Score: 6FDA approves sotatercept for pulmonary arterial hypertension - 1 month(s) ago
The FDA has approved sotatercept, an activin signaling inhibitor, for treating adults with pulmonary arterial hypertension, according to a manufacturer-issued press release.In September 2023, the FDA granted priority review to sotatercept (Winrevair, Merck).
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 6FDA approves sotatercept for pulmonary arterial hypertension - 1 month(s) ago
The FDA has approved sotatercept, an activin signaling inhibitor, for treating adults with pulmonary arterial hypertension, according to a manufacturer-issued press release.In September 2023, the FDA granted priority review to sotatercept (Winrevair, Merck).
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet
🚨FDA News🚨 The @US_FDA has approved #sotatercept (@Merck), an activin signaling inhibitor, for treating adults with #PAH. @CardiologyToday Read more🔽 https://t.co/eeKjZ2gfAG